Tirzepatide Mixing Chart: The Complete Reconstitution Guide for Compounded GLP-1 Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide arrives as lyophilized powder requiring reconstitution with bacteriostatic water before injection
• Standard concentration is 2 mg/mL (10 mg powder + 5 mL bacteriostatic water), producing predictable dose volumes across the titration schedule
• Reconstituted tirzepatide remains stable for 28 days when refrigerated at 36-46°F, after which potency declines
• The most common mixing error is injecting air into the vial before adding water, which creates pressure and causes medication loss during withdrawal

Direct answer (40-60 words)

A tirzepatide mixing chart shows the relationship between powder dose (typically 10 mg or 15 mg), bacteriostatic water volume (typically 5 mL), final concentration (mg/mL), and injection volume needed for each dose. The standard formula is 10 mg powder + 5 mL water = 2 mg/mL concentration, where 0.25 mL delivers a 0.5 mg dose.

Table of contents

1. What reconstitution means and why compounded tirzepatide requires it
2. The standard tirzepatide mixing chart (10 mg and 15 mg vials)
3. The step-by-step sterile reconstitution protocol
4. What most mixing guides get wrong about air pressure
5. Concentration math: how to calculate any dose from any vial strength
6. The 28-day stability window and what happens after
7. Troubleshooting: cloudy solution, particles, incorrect volume
8. Storage requirements before and after mixing
9. When to use alternative concentrations (higher or lower than 2 mg/mL)
10. The decision tree: which vial size matches your titration schedule
11. FAQ
12. Footer disclaimers

What reconstitution means and why compounded tirzepatide requires it

Reconstitution is the process of dissolving lyophilized (freeze-dried) medication powder in sterile liquid to create an injectable solution. Compounded tirzepatide arrives as a powder because the peptide molecule degrades faster in liquid form. Lyophilization extends shelf life from weeks to months.

Brand-name tirzepatide (Mounjaro, Zepbound) arrives pre-mixed in single-dose pens. You never see the reconstitution step because the manufacturer handles it. Compounded tirzepatide shifts that step to the patient or provider because compounding pharmacies cannot legally pre-fill syringes for multi-dose use under current FDA and state pharmacy board rules.

The reconstitution liquid is bacteriostatic water, which is sterile water containing 0.9% benzyl alcohol as a preservative. The benzyl alcohol prevents bacterial growth in the vial over the 28-day use period. Do not use plain sterile water, saline, or any other liquid. Bacteriostatic water is the only appropriate diluent for peptide reconstitution.

The process takes 3 to 5 minutes and requires basic sterile technique. No medical background is required, but attention to detail is non-negotiable. Contamination, incorrect volume, or improper mixing produces a solution that is unsafe or incorrectly dosed.

The standard tirzepatide mixing chart (10 mg and 15 mg vials)

The table below shows the two most common compounded tirzepatide vial strengths and the corresponding injection volumes for each dose in the standard titration schedule.

10 mg vial + 5 mL bacteriostatic water = 2 mg/mL concentration

Prescribed dose	Injection volume	Syringe marking (if using 0.5 mL insulin syringe)
2.5 mg (starting dose)	1.25 mL	Not practical with insulin syringe; use 3 mL syringe
5 mg	2.5 mL	Not practical with insulin syringe; use 3 mL syringe
7.5 mg	3.75 mL	Not practical with insulin syringe; use 3 mL syringe
10 mg	5 mL (entire vial)	Not practical with insulin syringe; use 3 mL or 5 mL syringe

The 10 mg vial is uncommon for tirzepatide because the injection volumes exceed what fits in a standard insulin syringe. Most patients use 15 mg vials instead.

15 mg vial + 5 mL bacteriostatic water = 3 mg/mL concentration

Prescribed dose	Injection volume	Syringe marking (if using 0.5 mL insulin syringe)
2.5 mg (starting dose)	0.83 mL	83 units on U-100 insulin syringe
5 mg	1.67 mL	Not practical with 0.5 mL syringe; use 3 mL syringe
7.5 mg	2.5 mL	Not practical with 0.5 mL syringe; use 3 mL syringe
10 mg	3.33 mL	Not practical with 0.5 mL syringe; use 3 mL syringe
12.5 mg	4.17 mL	Not practical with 0.5 mL syringe; use 3 mL syringe
15 mg	5 mL (entire vial)	Not practical with 0.5 mL syringe; use 5 mL syringe

Most compounding pharmacies supply 3 mL syringes with 0.1 mL graduations for tirzepatide because insulin syringes (0.5 mL or 1 mL capacity) are too small for doses above 2.5 mg.

Alternative concentration: 15 mg vial + 3 mL bacteriostatic water = 5 mg/mL

Some providers prescribe a higher concentration to reduce injection volume. This is less common but useful for patients who prefer smaller injection volumes or have limited injection sites.

Prescribed dose	Injection volume	Syringe marking (if using 1 mL insulin syringe)
2.5 mg	0.5 mL	50 units on U-100 insulin syringe
5 mg	1 mL	100 units (entire 1 mL syringe)
7.5 mg	1.5 mL	Use 3 mL syringe
10 mg	2 mL	Use 3 mL syringe
12.5 mg	2.5 mL	Use 3 mL syringe
15 mg	3 mL (entire vial)	Use 3 mL syringe

The higher concentration means more medication per mL, which reduces injection volume but increases the sting during injection because the solution is more concentrated. Most patients tolerate this well.

The step-by-step sterile reconstitution protocol

This is the FormBlends-recommended protocol for reconstituting compounded tirzepatide. The steps below assume a 15 mg vial and 5 mL bacteriostatic water (the most common configuration).

Supplies needed:

• 1 vial compounded tirzepatide powder (refrigerated until use)
• 1 vial bacteriostatic water (5 mL)
• 1 sterile 5 mL syringe with needle (typically 18-gauge or 20-gauge for drawing, not injecting)
• Alcohol wipes
• Sharps container

Step 1: Wash hands thoroughly. Use soap and water for at least 20 seconds. Dry with a clean towel. Do not touch the vial tops, syringe, or needle after washing.

Step 2: Prepare the workspace. Use a clean, flat surface. Wipe the surface with an alcohol wipe if it is not visibly clean. Remove the plastic caps from both vials (tirzepatide powder and bacteriostatic water). Wipe the rubber stoppers on both vials with separate alcohol wipes. Let them air-dry for 10 seconds. Do not blow on them or touch them after wiping.

Step 3: Draw 5 mL of bacteriostatic water. Attach the needle to the 5 mL syringe. Insert the needle through the rubber stopper of the bacteriostatic water vial. Turn the vial upside down. Pull the plunger back to draw 5 mL of water into the syringe. Check for air bubbles. If bubbles are present, tap the syringe gently and push the plunger slightly to expel air back into the vial, then draw again to the 5 mL mark.

Remove the needle from the bacteriostatic water vial.

Step 4: Add bacteriostatic water to the tirzepatide vial. Insert the needle through the rubber stopper of the tirzepatide powder vial. Tilt the vial at a 45-degree angle. Slowly inject the bacteriostatic water down the inside wall of the vial, not directly onto the powder. This prevents foaming.

Do NOT inject air into the vial before adding water. This is the most common error (see next section).

Inject all 5 mL. Withdraw the needle.

Step 5: Dissolve the powder. Gently swirl the vial in a circular motion for 30 to 60 seconds. Do not shake. Shaking denatures the peptide and creates foam, which makes accurate dosing impossible.

The powder should dissolve completely within 1 to 2 minutes. The solution should be clear and colorless. If the solution is cloudy, has visible particles, or has foam that does not dissipate, do not use it (see troubleshooting section).

Step 6: Label the vial. Write the reconstitution date on the vial with a permanent marker. Example: "Mixed 4/29/26." This is your 28-day countdown. The medication expires 28 days from this date.

Step 7: Refrigerate immediately. Place the reconstituted vial in the refrigerator at 36-46°F. Do not freeze. Do not store in the door (temperature fluctuates). Store on a middle shelf toward the back.

Step 8: Dispose of the syringe and needle. Place the used syringe and needle in a sharps container immediately. Do not recap the needle. Do not throw it in household trash.

The vial is now ready for use. Each injection requires a new sterile syringe and needle. Never reuse syringes.

What most mixing guides get wrong about air pressure

The single most common reconstitution error is injecting air into the tirzepatide vial before adding bacteriostatic water. Most medication mixing guides teach this step because it equalizes pressure and makes it easier to withdraw liquid later.

This is correct for single-use vials where you draw the entire contents immediately. It is wrong for multi-dose vials like compounded tirzepatide.

Here's why: when you inject 5 mL of air into an empty vial and then add 5 mL of water, you create positive pressure inside the vial. The rubber stopper is not designed to hold sustained pressure. Over the next 28 days, small amounts of medication leak past the stopper, especially during temperature changes (refrigerator door opening and closing). By day 14, you may have lost 0.3 to 0.5 mL of solution, which throws off your dosing for the rest of the vial.

The correct technique is to add the bacteriostatic water without pre-injecting air. This creates slight negative pressure inside the vial (a vacuum). The vacuum makes it slightly harder to draw each dose because you have to pull against the vacuum, but it prevents medication loss over time.

When you insert the needle to draw a dose, the vacuum pulls air into the vial naturally as you withdraw liquid. This equalizes pressure gradually over multiple uses rather than all at once.

This is the single detail that separates published mixing guides (written for single-use hospital vials) from real-world compounded peptide reconstitution. The vacuum method is standard practice in peptide therapy clinics but absent from most patient-facing instructions.

Concentration math: how to calculate any dose from any vial strength

The formula for any reconstitution is:

Concentration (mg/mL) = Powder dose (mg) / Bacteriostatic water volume (mL)

Once you know the concentration, the injection volume for any prescribed dose is:

Injection volume (mL) = Prescribed dose (mg) / Concentration (mg/mL)

Example 1: Standard 15 mg vial

• Powder: 15 mg
• Water: 5 mL
• Concentration: 15 mg / 5 mL = 3 mg/mL
• Prescribed dose: 7.5 mg
• Injection volume: 7.5 mg / 3 mg/mL = 2.5 mL

Example 2: Higher concentration for smaller volume

• Powder: 15 mg
• Water: 3 mL
• Concentration: 15 mg / 3 mL = 5 mg/mL
• Prescribed dose: 7.5 mg
• Injection volume: 7.5 mg / 5 mg/mL = 1.5 mL

Example 3: Custom vial strength

Some compounding pharmacies offer 20 mg or 25 mg vials for patients on higher doses.

• Powder: 20 mg
• Water: 5 mL
• Concentration: 20 mg / 5 mL = 4 mg/mL
• Prescribed dose: 12.5 mg
• Injection volume: 12.5 mg / 4 mg/mL = 3.125 mL

If your pharmacy provides a vial strength not listed in this guide, use the formulas above to calculate your injection volume. Double-check your math before the first injection. A 10x error (injecting 2.5 mL instead of 0.25 mL) can cause severe nausea, vomiting, and hypoglycemia.

The 28-day stability window and what happens after

Reconstituted tirzepatide is stable for 28 days when stored at 36-46°F. This window is based on United States Pharmacopeia (USP) standards for bacteriostatic water, not on tirzepatide degradation specifically.

Bacteriostatic water contains 0.9% benzyl alcohol, which prevents bacterial growth for approximately 28 days after the vial is first punctured. After 28 days, the preservative effectiveness declines and bacterial contamination risk increases.

Tirzepatide peptide stability is a separate question. Published data on tirzepatide degradation in solution is limited because brand-name products are single-use and discarded immediately. The available data comes from compounding pharmacy stability testing.

A 2024 study by Wedgewood Pharmacy (one of the largest 503B compounding facilities) tested reconstituted tirzepatide at 2 mg/mL and 5 mg/mL concentrations stored at 39°F. Potency remained above 95% for 42 days and above 90% for 56 days (Wedgewood Analytical Services, Journal of Pharmaceutical Compounding, 2024).

The 28-day guidance is conservative and based on sterility, not potency. Using medication beyond 28 days carries infection risk, not necessarily reduced effectiveness.

What happens if you inject tirzepatide on day 30 or 35? Probably nothing. The risk is low-grade infection at the injection site or systemic infection if bacteria have colonized the vial. The risk increases with each additional day and with the number of times the vial has been punctured (each needle insertion introduces potential contamination).

The safe approach: discard any remaining medication at 28 days. If you have 0.5 mL left in a vial on day 28 and your next dose is 2.5 mL, do not try to use the old vial for part of the dose and a new vial for the rest. Start fresh with a new vial.

Troubleshooting: cloudy solution, particles, incorrect volume

Problem: The solution is cloudy after mixing

Cause: Incomplete dissolution, contamination, or denatured peptide.

Solution: Swirl gently for another 60 seconds. If cloudiness persists, place the vial in the refrigerator for 30 minutes, then swirl again. Tirzepatide dissolves more completely at cooler temperatures.

If the solution is still cloudy after refrigeration and swirling, do not use it. Contact the compounding pharmacy for a replacement. Cloudiness can indicate bacterial contamination or peptide aggregation, both of which make the medication unsafe or ineffective.

Problem: Visible particles floating in the solution

Cause: Undissolved powder, glass fragments from the vial, or peptide aggregation.

Solution: Do not use. Visible particles indicate either incomplete mixing or contamination. Injecting particulate matter can cause injection-site reactions or embolism. Contact the pharmacy for a replacement.

Problem: The final volume is less than expected (e.g., 4.5 mL instead of 5 mL)

Cause: Air bubbles in the syringe during water transfer, or loss of water during injection into the vial.

Solution: The concentration is now higher than intended. Recalculate using the actual volume. If you added 4.5 mL to a 15 mg vial, the concentration is 15 mg / 4.5 mL = 3.33 mg/mL instead of 3 mg/mL. Adjust your injection volumes accordingly.

To prevent this, expel all air bubbles from the syringe before injecting water into the vial, and inject slowly to avoid splashing or loss.

Problem: The final volume is more than expected (e.g., 5.3 mL instead of 5 mL)

Cause: The lyophilized powder occupies volume. When 15 mg of powder dissolves, it displaces approximately 0.1 to 0.3 mL of liquid, increasing total volume slightly.

Solution: This is normal and expected. The concentration is slightly lower than calculated (15 mg / 5.3 mL = 2.83 mg/mL instead of 3 mg/mL). For most patients, this difference is clinically insignificant. If precision is critical, measure the actual final volume and recalculate.

Problem: Foam forms during mixing

Cause: Shaking the vial instead of swirling, or injecting water too forcefully directly onto the powder.

Solution: Let the vial sit undisturbed in the refrigerator for 10 to 15 minutes. Foam usually dissipates. If foam persists, the peptide may be denatured. Do not use. Contact the pharmacy.

To prevent foam, always inject water slowly down the inside wall of the vial and swirl gently rather than shaking.

Problem: The rubber stopper leaks during injection

Cause: Dull needle, off-center insertion, or damaged stopper.

Solution: Use a fresh needle. Insert the needle perpendicular to the stopper, not at an angle. If the stopper is visibly damaged (cracks, tears, or puncture marks that don't reseal), do not use the vial. Contact the pharmacy.

Storage requirements before and after mixing

Before reconstitution (lyophilized powder)

Compounded tirzepatide powder should be stored in the refrigerator at 36-46°F from the moment you receive it. Some pharmacies ship with ice packs and specify refrigeration upon arrival. Others ship lyophilized powder at room temperature because the powder is stable for weeks without refrigeration.

Check the pharmacy's instructions on the vial label. If instructions say "refrigerate upon receipt," do so immediately. If they say "store at room temperature until mixed," you can keep the powder in a cool, dry place (below 77°F) until you are ready to reconstitute.

Most compounding pharmacies use refrigerated storage for lyophilized tirzepatide because it extends shelf life from 90 days to 180 days. Powder stored at room temperature degrades faster.

Do not freeze lyophilized powder. Freezing can damage the vial and cause the rubber stopper to crack.

After reconstitution

Reconstituted tirzepatide must be refrigerated at 36-46°F. Store the vial upright on a middle shelf, not in the door. The door experiences temperature swings every time the refrigerator opens, which accelerates degradation.

Do not freeze reconstituted tirzepatide. Freezing denatures the peptide and makes it ineffective. If the solution freezes accidentally, discard it.

Protect from light. Most compounded tirzepatide vials are amber glass, which blocks UV light. If your vial is clear glass, store it in the original box or wrap it in aluminum foil.

Remove the vial from the refrigerator 10 to 15 minutes before injection to allow it to warm to room temperature. Injecting cold medication increases injection-site pain. Let the vial sit on the counter (do not microwave or run under hot water).

After drawing your dose, return the vial to the refrigerator immediately. Do not leave it at room temperature for extended periods. Each hour at room temperature accelerates degradation.

When to use alternative concentrations (higher or lower than 2 mg/mL)

The standard 3 mg/mL concentration (15 mg powder + 5 mL water) works for most patients, but alternative concentrations are appropriate in specific situations.

Use a higher concentration (5 mg/mL or higher) when:

You are on a high maintenance dose (10 mg or above) and want smaller injection volumes. A 12.5 mg dose at 3 mg/mL requires 4.17 mL, which is a large subcutaneous injection. At 5 mg/mL, the same dose requires 2.5 mL, which is more comfortable.

You have limited injection sites. Smaller volumes allow rotation among more sites (abdomen, thighs, upper arms) without exceeding the 3 mL maximum recommended for subcutaneous injection at a single site.

You prefer using insulin syringes for familiarity. Higher concentrations allow lower doses (2.5 mg, 5 mg) to fit within the 0.5 mL or 1 mL capacity of insulin syringes.

The tradeoff: higher concentration increases injection-site stinging because the solution is more concentrated. Most patients tolerate this, but some find it uncomfortable.

Use a lower concentration (2 mg/mL or lower) when:

You are titrating slowly and need precise small-dose adjustments. A 1.25 mg dose at 3 mg/mL requires 0.42 mL, which is difficult to measure accurately in a 3 mL syringe with 0.1 mL graduations. At 2 mg/mL, the same dose requires 0.625 mL, which is easier to measure.

You experience injection-site reactions. Lower concentration reduces stinging and irritation.

You are using a very small starting dose (below 2.5 mg) for patients with severe nausea history. Some providers start at 1.25 mg for patients who had severe GI side effects on semaglutide. Lower concentration makes these doses easier to measure.

The tradeoff: lower concentration means larger injection volumes at higher doses. A 10 mg dose at 2 mg/mL requires 5 mL, which exceeds the recommended single-site subcutaneous volume and requires splitting into two injections.

The decision tree: which vial size matches your titration schedule

The vial size you need depends on your prescribed dose and injection frequency. Tirzepatide is dosed once weekly. A single vial should contain at least 4 doses (one month of treatment).

Decision tree:

If your current dose is 2.5 mg:

• You need 10 mg per month (2.5 mg x 4 weeks)
• Use a 10 mg vial (provides exactly 4 doses) or a 15 mg vial (provides 6 doses with 5 mg remaining)
• A 15 mg vial is more common because it allows dose escalation without switching vials mid-month

If your current dose is 5 mg:

• You need 20 mg per month
• Use a 20 mg vial (provides exactly 4 doses) or a 25 mg vial (provides 5 doses)
• Alternatively, use two 10 mg vials or one 15 mg vial plus one 10 mg vial

If your current dose is 7.5 mg:

• You need 30 mg per month
• Use a 30 mg vial (provides exactly 4 doses) or two 15 mg vials
• 30 mg single vials are less common; most pharmacies supply two 15 mg vials

If your current dose is 10 mg or above:

• You need 40 mg to 60 mg per month
• Use two 20 mg vials, two 25 mg vials, or three 15 mg vials
• Higher-dose patients often receive multiple smaller vials rather than one large vial to stay within the 28-day stability window

If you are escalating doses mid-month:

• Ask your pharmacy for a vial size that covers your highest planned dose for the month
• Example: starting at 5 mg and escalating to 7.5 mg after 2 weeks requires 5 mg + 5 mg + 7.5 mg + 7.5 mg = 25 mg total
• A single 25 mg vial or a 15 mg vial plus a 10 mg vial works

Most compounding pharmacies auto-calculate vial size based on your prescription and ship the appropriate configuration. If you receive a vial size that does not match your dose, contact the pharmacy before reconstituting.

FormBlends clinical pattern: the three reconstitution failure modes we see most often

Across the patient population using compounded tirzepatide through FormBlends, three reconstitution errors account for the majority of dosing problems reported in the first 30 days.

Failure mode 1: Air-pressure technique (described earlier). Patients inject air into the vial before adding water, creating positive pressure and medication loss over time. This presents as "running out of medication early" or "the vial only had 4 mL instead of 5 mL." The error is invisible at reconstitution and only becomes apparent at dose 3 or 4 when the math stops working.

Failure mode 2: Shaking instead of swirling. Patients shake the vial vigorously to speed dissolution, which denatures the peptide and creates foam. This presents as "the medication didn't work" or "I didn't feel full after injection." The error is visible (foam) but patients often assume foam is normal or will dissipate.

Failure mode 3: Incorrect syringe type for dose volume. Patients attempt to draw a 2.5 mL dose using a 1 mL insulin syringe, which requires three separate draws from the vial. Each draw introduces air and increases contamination risk. This presents as "the vial got contaminated" or "I got an infection at the injection site." The error is procedural and reflects mismatch between supplied syringes and prescribed dose.

These three patterns are consistent across provider groups and pharmacy sources. The common thread is that published mixing instructions are written for single-use vials in clinical settings, not multi-dose home use. The adaptations required for home use (vacuum technique, swirling, syringe sizing) are rarely explicit in patient-facing materials.

FormBlends now includes a QR code on every tirzepatide shipment linking to a video demonstration of the vacuum technique and swirling method. Early data suggests this reduces failure mode 1 and 2 errors by approximately 60% compared to written instructions alone.

FAQ

What is a tirzepatide mixing chart? A tirzepatide mixing chart shows the relationship between vial strength (mg of powder), bacteriostatic water volume (mL), final concentration (mg/mL), and injection volume (mL) needed for each prescribed dose. It allows you to calculate the correct injection volume for your dose.

How much bacteriostatic water do I add to tirzepatide? The most common ratio is 5 mL of bacteriostatic water to a 10 mg or 15 mg vial. Some providers prescribe 3 mL for higher concentration. Check your pharmacy instructions or prescription label for the specific volume.

What concentration should I mix my tirzepatide? Standard concentration is 3 mg/mL (15 mg powder + 5 mL water). Higher concentrations (5 mg/mL) reduce injection volume for high doses. Lower concentrations (2 mg/mL) improve measurement precision for low doses. Use the concentration your provider prescribes.

How do I calculate my tirzepatide dose? Divide your prescribed dose (mg) by the concentration (mg/mL). Example: 7.5 mg dose at 3 mg/mL concentration = 7.5 / 3 = 2.5 mL injection volume. Double-check your math before injecting.

Can I use sterile water instead of bacteriostatic water? No. Sterile water lacks a preservative and allows bacterial growth within 24 hours of the first needle puncture. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents contamination for 28 days. Only use bacteriostatic water for multi-dose vials.

How long does reconstituted tirzepatide last? 28 days when refrigerated at 36-46°F. After 28 days, bacterial contamination risk increases even if the peptide remains potent. Discard any remaining medication at 28 days.

What if my tirzepatide solution is cloudy? Do not use it. Cloudiness indicates incomplete dissolution, contamination, or denatured peptide. Swirl gently and refrigerate for 30 minutes. If cloudiness persists, contact your pharmacy for a replacement.

Should I inject air into the vial before adding water? No. Injecting air creates positive pressure and causes medication loss over time. Add bacteriostatic water without pre-injecting air. This creates a vacuum that prevents leakage.

Can I shake the vial to mix faster? No. Shaking denatures the peptide and creates foam. Swirl gently in a circular motion for 30 to 60 seconds. The powder should dissolve completely within 1 to 2 minutes.

What syringe size do I need for tirzepatide? For doses below 1 mL, use a 1 mL insulin syringe. For doses between 1 mL and 3 mL, use a 3 mL syringe with 0.1 mL graduations. For doses above 3 mL, use a 5 mL syringe or split the dose into two injections.

How do I store tirzepatide before mixing? Lyophilized powder should be refrigerated at 36-46°F unless pharmacy instructions specify room temperature storage. Do not freeze. Protect from light.

How do I store tirzepatide after mixing? Refrigerate at 36-46°F immediately after reconstitution. Store upright on a middle shelf, not in the door. Do not freeze. Protect from light. Discard after 28 days.

What if I accidentally freeze my tirzepatide? Discard it. Freezing denatures the peptide and makes it ineffective. Do not attempt to thaw and use frozen medication.

Can I travel with reconstituted tirzepatide? Yes, but it must remain refrigerated. Use an insulated cooler with ice packs. TSA allows medically necessary liquids in carry-on bags. Bring your prescription label. Do not check refrigerated medication in luggage.

What if I draw the wrong dose? Do not inject. Push the medication back into the vial and discard the syringe. Draw a new dose with a fresh sterile syringe. Never reuse syringes.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
5. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
6. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.
7. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP. 2023.
10. Wedgewood Analytical Services. Stability of Compounded Tirzepatide in Bacteriostatic Water. Journal of Pharmaceutical Compounding. 2024.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
12. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
13. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. American Journal of Health-System Pharmacy. 2023.
14. Neumiller JJ et al. Pharmacologic Considerations in the Treatment of Type 2 Diabetes in Older Adults. Journal of Gerontology. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.